XML 157 R106.htm IDEA: XBRL DOCUMENT
v3.23.4

Subsequent Events - Additional Information (Details) - $ / shares | Sep. 29, 2023 | Sep. 08, 2023 | Jul. 07, 2023 | Jun. 22, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2021
--- | --- | --- | --- | --- | --- | --- | ---
Subsequent Event [Line Items] |  |  |  |  |  |  |
Common stock, par value |  |  |  |  | $ 0.0001 | $ 0.0001 | $ 0.0001
Stockholders' equity, reverse stock split |  | 1-for-25 |  |  |  |  |
Reduction in the total number of authorized shares |  | 25 |  |  |  |  |
Parapyre Option Obligation |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Share-based payment award, term | 10 years |  |  |  |  |  |
Spyre Therapeutics, Inc. | Common Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition |  |  |  | 517,809 |  |  |
Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition |  |  |  | 364,887 |  |  |
Subsequent Event |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Common stock, par value |  | $ 0.0001 |  |  |  |  |
Stockholders' equity, reverse stock split |  | 1-for-25 |  |  |  |  |
Subsequent Event | Parapyre Option Obligation |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Share-based payment award, term | 10 years |  |  |  |  |  |
Subsequent Event | Maximum |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Reduction in the total number of authorized shares |  | 500,000,000 |  |  |  |  |
Subsequent Event | Minimum |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Reduction in the total number of authorized shares |  | 20,000,000 |  |  |  |  |
Subsequent Event | Spyre Therapeutics, Inc. | Common Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition |  |  | 517,809 |  |  |  |
Subsequent Event | Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition |  |  | 364,887 |  |  |  |

X
- Definition Asset acquisition consideration transferred equity interest issued and issuable, shares. + References No definition available. + Details
Name: | agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | agle_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reduction in the number of shares during the period as a result of a reverse stock split. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details
Name: | us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |